Biomaterials liability reform action urged by AMA as bill stalls in Congress.
This article was originally published in The Gray Sheet
Executive SummaryBIOMATERIALS LIABILITY REFORM CONGRESSIONAL ACTION URGED BY AMA in a resolution passed at the group's House of Delegates meeting held June 18-22 in Chicago. The American Medical Association will urge Congress "to expedite legislation that has been passed...to afford the protection of the law to manufacturers of critically important medical materials and devices and the professionals who use them."
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.